Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease
DOI:
https://doi.org/10.22141/2307-1257.7.4.2018.148522Keywords:
anemia, chronic kidney disease, hypoxia-inducible factor, prolyl hydroxylase inhibitor, roxadustat, vadadustat, daprodustat, molidustat, reviewAbstract
Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated with chronic kidney disease, which led to the development of therapeutic agents for treatment. A new class of agents for the treatment of anemia in chronic kidney disease are prolyl hydroxylase inhibitors, which stabilize hypoxia-inducible factor that is the key regulator of erythropoiesis and iron metabolism. Currently, drugs such as roxadustat (FG-4592), vadadustat (AKB-6548), daprodustat (GSK1278863) are undergoing phase III clinical trials, and molidustat (BAY 85-3934) — phase II.Downloads
References
Wang H., Naghavi M., Allen C. et al. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 // Lancet. — 2016. — 388. — Р. 1459-544. doi: 10.1016/S0140-6736(16)31012-1.
Neuen B.L., Chadban S.J., Demaio A.R. et al. Chronic kidney disease and the global NCDs agenda // BMJ Glob Health. — 2017. — 2. — e000380. doi: 10.1136/bmjgh-2017-000380.
Babitt J.L., Lin H.Y. Mechanisms of Anemia in CKD // J. Am. Soc. Nephrol. — 2012. — 23. — Р. 28. doi: 10.1681/ASN.2011111078.
Li Y., Shi H., Wang W.M., Peng A., Jiang G.R., Zhang J.Y., Ni Z.H., He L.Q., Niu J.Y., Wang N.S. et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study // Medicine (Baltimore). — 2016. — 95. — e3872. doi: 10.1097/MD.0000000000003872.
Macdougall I.C., Obrador G.T. How important is transfusion avoidance in 2013? // Nephrol. Dial. Transplant. — 2013. — 28. — Р. 1092-1099. doi: 10.1093/ndt/gfs575.
Vaziri N.D. Safety issues in iron treatment in CKD // Semin. Nephrol. — 2016. — 36. — Р. 112-118. doi:10.1016/j.semnephrol.2016.02.005.
Artunc F., Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease // Nephrol. Dial. Transplant. — 2007. — 22. — Р. 2900-2908. doi: 10.1093/ndt/gfm316.
Windsor J.S., Rodway G.W. Heights and haematology: the story of haemoglobin at altitude // Postgrad. Med. J. — 2007. — 83. — Р. 148-151. doi: 10.1136/pgmj.2006.049734.
Miyake T., Kung C.K., Goldwasser E. Purification of human erythropoietin // J. Biol. Chem. — 1977. — 252. — Р. 5558-5564.
Goldwasser E. Erythropoietin and its mode of action // Blood Cells. — 1984. — 10. — Р. 147-162.
Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J., Mufson A., Seehra J., Jones S.S., Hewick R., Fritsch E.F. et al.: Isolation and characterization of genomic and cDNA clones of human erythropoietin // Nature. — 1985. — 313. —Р. 806-810.
Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z. et al. Cloning and expression of the human erythropoietin gene // Proc. Natl Acad. Sci. USA. — 1985. — 82. — Р. 7580-7584.
Eschbach J.W., Egrie J.C., Downing M.R. et al. The Use of Recombinant Human Erythropoietin (r-HuEPO): Effect in End-Stage Renal Disease (ESRD) // Friedman, Beyer, DeSanto, Giordano, eds. Prevention of Chronic Uremia. — Philadelphia, PA: Field and Wood Inc., 1989. — Р. 148-155.
Takeuchi M., Kobata A. Structures and functional roles of the sugar chains of human erythropoietins // Glycobiology. — 1991. — 1(4). — Р. 337-346. doi: 10.1093/glycob/1.4.337.
Stone W.J., Graber S.E., Krantz S.B. et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial // Am. J. Med. Sci. — 1988. — 296(3). — Р. 171-179.
Horowitz J., Collazo-Maldonado R. Ironing Out the Details: New Anemia Treatments for Patients with Chronic Kidney Disease // Graduate Medical Education Journal of Methodist Health System, Dallas, Texas, Spring. — 2016. — Vol. 13, № 2. — P. 1-7.
AHFS Drug Information, ed AHFS 2013 Drug Information. — Bethesda, MD: American Society of Health-System Pharmacists, 2013.
Lexi-Comp I., ed. Drug Information Handbook. —
st ed. — Hudson, OH: Lexi-Comp, 2013.
Del Vecchio L., Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease // Expert Opin Drug Saf. — 2016. — 15(8). — Р. 1021-30. doi: 10.1080/14740338.2016.1182494.
Unger E.F., Thompson A.M., Blank M.J., Temple R. Erythropoiesis-stimulating agents — time for a reevaluation // N. Engl. J. Med. — 2010. — 362(3). — Р. 189. doi:10.1056/ NEJMp0912328.
Semenza, G.L., Wang, G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation // Mol. Cell. Biol. — 1992. — 12. — Р. 5447-5454.
Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1 // J. Biol. Chem. — 1995. — 270. — Р. 1230-1237.
Jaakkola P., Mole D.R., Tian Y.M. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation // Science. — 2001. — 292(5516). — Р. 468-472. doi: 10.1126/science.1059796.
Ivan M., Kondo K., Yang H. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing // Science. — 2001. — 292(5516). — Р. 464-468. doi:10.1126/science.1059817.
Vogel S., Wottawa M., Farhat K. et al. Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation // J. Biol. Chem. — 2010. — 285(44). — Р. 33756-33763. doi: 10.1074/jbc.M110.132985.
Lee D.C., Sohn H.A., Park Z.Y. et al. A lactate-induced response to hypoxia // Cell. — 2015. — 161(3). — Р. 595-609. doi: 10.1016/j.cell.2015.03.011.
Tanaka T., Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents // Exp. Cell. Res. — 2012. — 318(9). — Р. 1068-1073. doi: 10.1016/j.yexcr.2012.02.035.
Epstein A.C., Gleadle J.M., McNeill L.A. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation // Cell. — 2001. — 107(1). — Р. 43-54.
Gupta N.,Wish J.B. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD // Am. J. Kidney Dis. — 2017. — 69(6). — Р. 815-826. doi: 10.1053/j.ajkd.2016.12.011.
Locatelli et al. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients // Am. J. Nephrol. — 2017. — 45. — Р. 187-199. doi: 10.1159/000455166.
Besarab A., Provenzano R., Hertel J. et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients // Nephrol. Dial. Transplant. — 2015. — 30(10). — Р. 1665-73. doi: 10.1093/ndt/gfv302.
U.S. National Institutes of Health. Roxadustat. ClinicalTrials. gov // http://www.clinicaltrials.gov. Accessed 18 Nov 2016.
Provenzano R., Besarab A., Wright S. et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a Phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study // Am. J. Kidney Dis. — 2016. — 67(6). — Р. 912-24. doi: 10.1053/j.ajkd.2015.12.020.
Becker K., Saad M. A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat // J. Kidney. — 2017. — 3. — 1. doi: 10.4172/2472-1220.1000139.
Besarab A., Chernyavskaya E., Motylev I., Shutov E., Kumbar L.M., Gurevich K., Chan D.T., Leong R., Poole L., Zhong M., Saikali K.G., Franco M., Hemmerich S., Yu K.H., Neff T.B. Roxadustat (FG-4592): correction of anemia in incident dialysis patients // J. Am. Soc. Nephrol. — 2016. — 27. — Р. 1225-1233. doi: 10.1681/ASN.2015030241.
Martin E.R., Smith M.T., Maroni B.J., Zuraw Q.C., deGoma E.M. Clinical trial of Vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease // Am. J. Nephrol. — 2017. — 45. — Р. 380-388. doi: 10.1159/000464476.
Pergola P.E., Spinowitz B.S., Hartman C.S., Maroni B.J., Haase V.H. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease // Kidney Int. — 2016. — 90. — Р. 1115-1122. doi: 10.1016/j.kint.2016.07.019.
European Medicines Agency (EMA) vadadustat PIP decision. — Available at: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500223972.pdf. Accessed 31 July 2017.
Brigandi R.A., Biju M., Ariazi J.L., Kumar S., Duffy K.J., Erickson-Miller C.L. Prolyl hydroxylase inhibitors reduce hepcidin levels and affect multiple iron-modulating proteins // J. Am. Soc. Nephrol. — 2010. — 21. — 722A.
Brigandi R.A., Russ S.F., Oei C., Westerman M., Olbina G., Robson R., Kumar S. Modulation of erythropoietin by prolyl hydroxylase inhibitor in renal impaired patients in a single dose cross-over study // J. Am. Soc. Nephrol. — 2011. — 23. — 203A.
Brigandi R.A., Johnson B., Oei C., Westerman M., Olbina G., de Zoysa J., Roger S.D., Sahay M., Cross N., McMahon L., Guptha V., Smolyarchuk E.A., Singh N., Russ S.F., Kumar S. PHI112844 Investigators: A novel hypoxiainducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2a randomized trial // Am. J. Kidney Dis. — 2016. — 67. —Р. 861-871. doi: 10.1053/j.ajkd.2015.11.021.
Holdstock L., Meadowcroft A.M., Maier R., Johnson B.M., Jones D., Rastogi A., Zeig S., Lepore J.J., Cobitz A.R. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia // J. Am. Soc. Nephrol. — 2016. — 27. — Р. 1234-1244. doi: 10.1681/ASN.2014111139.
Macdougall I.C., Akizawa T., Berns J., Lentini S., Bernhardt T. Molidustat increases heamoglobin in erythropoiesis stimulating agents (ESA)-naive anemic patients with chronic kidney disease not on dialysis (CKD-ND). — Vienna, 53rd Congress European Renal Association — European Dialysis and Transplant Association, 2016. — SO036.
Macdougall I.C., Akizawa T., Berns J., Lentini S., Bernhardt T., Kruger T. Safety and efficacy of molidustat in erythropoiesis stimultaing agents (ESA) pre-treated anemic patients with chronic kidney disease not on dialysis (CKD-ND). — Vienna, 53rd Congress European Renal Association — European Dialysis and Transplant Association, 2016. — SP309.
Barrett T.D., Palomino H.L., Brondstetter T.I., Kanelakis K.C., Wu X., Yan W., Merton K.P., Schoetens F., Ma J.Y., Skaptason J., Gao J., Tran D.T., Venkatesan H., Rosen M.D., Shankley N.P., Rabinowitz M.H. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats // Br. J. Pharmacol. — 2015. — 172. — Р. 4078-4088. doi: 10.1111/bph.13188.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 O.O. Melnyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 
ISSN 
